These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 15006716

  • 1. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J, Westphal S, Luley C.
    Expert Opin Drug Saf; 2004 Mar; 3(2):101-11. PubMed ID: 15006716
    [Abstract] [Full Text] [Related]

  • 2. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V, Stulc T, Kozich V, Grauova B, Krijt J, Wichterle D, Haas T, Malik J, Hradec J, Ceska R.
    Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
    [Abstract] [Full Text] [Related]

  • 3. Homocysteine elevation with fibrates: is it a class effect?
    Harats D, Yodfat O, Doolman R, Gavendo S, Marko D, Shaish A, Sela BA.
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 5. Effect of drugs on homocysteine concentrations.
    Dierkes J, Westphal S.
    Semin Vasc Med; 2005 May; 5(2):124-39. PubMed ID: 16047265
    [Abstract] [Full Text] [Related]

  • 6. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 7. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M.
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [Abstract] [Full Text] [Related]

  • 8. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
    Yeganeh B, Moshtaghi-Kashanian GR, Declercq V, Moghadasian MH.
    J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
    [Abstract] [Full Text] [Related]

  • 9. [Micronized fenofibrate and LDL-cholesterol subfractions].
    Soska V.
    Vnitr Lek; 1999 Jul; 45(7):441-3. PubMed ID: 11045166
    [Abstract] [Full Text] [Related]

  • 10. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
    Hernández C, Lecube A, Barberá G, Chacón P, Lima J, Simó R.
    Med Sci Monit; 2003 Mar; 9(3):CR114-9. PubMed ID: 12640339
    [Abstract] [Full Text] [Related]

  • 11. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 13. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
    Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ, FIELD study investigators.
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
    [Abstract] [Full Text] [Related]

  • 14. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
    Vergès B.
    Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
    [Abstract] [Full Text] [Related]

  • 15. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 16. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
    Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS.
    Am Heart J; 2004 Oct 22; 148(4):635-40. PubMed ID: 15459594
    [Abstract] [Full Text] [Related]

  • 17. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 22; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacologic treatment of lipid metabolism disorders].
    Gmiński J.
    Wiad Lek; 1996 Nov 22; 49(7-12):173-81. PubMed ID: 9214849
    [Abstract] [Full Text] [Related]

  • 19. Combination statin-fibrate therapy: safety aspects.
    Franssen R, Vergeer M, Stroes ES, Kastelein JJ.
    Diabetes Obes Metab; 2009 Feb 22; 11(2):89-94. PubMed ID: 18518891
    [Abstract] [Full Text] [Related]

  • 20. Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
    de Lorgeril M, Salen P, Guiraud A, Zeghichi S, Boucher F, de Leiris J.
    Nutr Metab Cardiovasc Dis; 2005 Feb 22; 15(1):36-41. PubMed ID: 15871849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.